Genmab Raises $4.7M Through Employee Warrant Exercise

Genmab has issued a capital increase of 4,563 shares following employee warrant exercise, raising approximately DKK 4.7 million. The increase represents about 0.01% of the company's share capital and will be listed on Nasdaq Copenhagen. The stock is currently rated as a Hold with a $24.00 price target.

Copenhagen, Denmark – Genmab A/S (Nasdaq: GMAB) has announced a capital increase of 4,563 shares following the exercise of employee warrants, raising approximately DKK 4.7 million. The increase, which represents about 0.01% of the company's share capital, will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments, giving rights to dividends and other rights in relation to the company as of subscription [1].

The capital increase is expected to be finalized shortly. The shares are subscribed in cash at the following prices per share of nominally DKK 1: 2,580 shares at DKK 1,025.00, 1,874 shares at DKK 1,050.00, and 109 shares at DKK 1,161.00. The total nominal value of Genmab A/S' share capital after the capital increase is DKK 64,158,817, made up of 64,158,817 shares of a nominal value of DKK 1 each, corresponding to 64,158,817 votes [1].

Analysts have rated Genmab as a Hold with a $24.00 price target, according to TipRanks, which aggregates data from 7 analysts. The average price target is $31.08, with a high forecast of $46.00 and a low forecast of $24.00, representing a 45.03% change from the last price of $21.43 [3].

References:
[1] https://ir.genmab.com/news-releases/news-release-details/capital-increase-genmab-result-employee-warrant-exercise-87
[2] https://finance.yahoo.com/news/capital-increase-genmab-result-employee-183600952.html
[3] https://www.tipranks.com/stocks/gmab/forecast